French Public Health Code
In forceI. - Establishments authorised for systemic medicinal treatments for cancer with designation B or C must have on site :
1° The organisation of a medical permanence at least by means of operational on-call duty;
2° A continuous surveillance unit;
3° An organisation allowing specialised and reinforced care for patients whose treatment of malignant haemopathy or malignant solid tumour by intensive chemotherapy results in foreseeable aplasia of more than eight days, 24 hours a day, 7 days a week during the treatment period. To this end, a permanent medical presence is organised on site;
4° For the holder of an authorisation for systemic medicinal treatments for cancer with mention B, a haematological intensive care unit for the care of patients with haematological malignant tumours or solid malignant tumours in a situation of aplasia caused by intensive chemotherapy;
For the holder of an authorisation for systemic medicinal treatments for cancer with mention C, a paediatric haematological intensive care unit mentioned in 4° of article R. 6123-34-2 or an intensive care unit mentioned in 1°, 2° or 3° of article R. 6123-34-2 allowing the treatments mentioned in the previous paragraph;
II. - It has an organisation, in place or by means of an agreement, guaranteeing access for aplastic patients at risk of multi-organ failure to an intensive care unit which is close enough and accessible enough to guarantee patient safety and which has an air decontamination system.
